SCHEMBL160586

SCHEMBL160586

Cc1nc2c(=O)[nH]c(N)nc2[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.53
KDM4E B2RXH2 1/20 0.53
LMNA P02545 1/20 0.53
GLA P06280 1/20 0.53
PMP22 Q01453 1/20 0.53
HSD17B10 Q99714 1/20 0.53
MAPT P10636 1/20 0.46
MITF O75030 1/20 0.44
TP53 P04637 1/20 0.44
THRB P10828 1/20 0.44
ALOX15 P16050 1/20 0.44
HBB P68871 1/20 0.44
HIF1A Q16665 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.42
PARP1 P09874 1/20 0.42
DYRK1A Q13627 1/20 0.42
PNP P00491 3/20 0.41
XDH P47989 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14337027 0.83 PARP1 (0.50) ALDH1A1KDM4EPMP22HSD17B10L3MBTL1
8-Aminoguanine SCHEMBL21760 0.83 KDM4E (0.60) ALDH1A1KDM4ELMNAGLAPMP22
SCHEMBL29819457 0.82 KDM4E (0.51) ALDH1A1KDM4ELMNAGLAPMP22
SCHEMBL1043887 0.79 KDM4E (0.49) ALDH1A1KDM4ELMNAGLAPMP22
SCHEMBL2206472 0.76 KDM4E (0.53) ALDH1A1KDM4ELMNAGLAPMP22
SCHEMBL844206 0.76 KDM4E (0.53) ALDH1A1KDM4ELMNAGLAPMP22
SCHEMBL9115 0.76 KDM4E (0.53) ALDH1A1KDM4ELMNAGLAPMP22
SCHEMBL158423 0.76 KDM4E (0.53) ALDH1A1KDM4ELMNAGLAPMP22
SCHEMBL42761 0.76 KDM4E (0.53) ALDH1A1KDM4ELMNAGLAPMP22
SCHEMBL6686385 0.76 KDM4E (0.53) ALDH1A1KDM4ELMNAGLAPMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1389 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026099316-A1 COMPOUNDS AND METHODS FOR REDUCING ARHGEF6 EXPRESSION ASTRAZENECA AB (SE) 2026-05-15 WO claimed
US-20250295658-A1 ANTIPARASITIC AGENTS AND METHODS WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH 2025-09-25 US claimed
WO-2023215819-A2 ANTIPARASITIC AGENTS AND METHODS WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2023-11-09 WO claimed
US-20220282275-A1 G-TO-T BASE EDITORS AND USES THEREOF THE BROAD INSTITUTE, INC. (US) 2022-09-08 US claimed
EP-3510170-B1 CONVERTIBLE ADAPTERS TECHNISCHE HOCHSCHULE WILDAU (DE) 2021-10-13 EP claimed
WO-2020102659-A1 G-TO-T BASE EDITORS AND USES THEREOF THE BROAD INSTITUTE, INC. (US) 2020-05-22 WO claimed
US-9725474-B2 Modified nucleic acid TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-08-08 US claimed
US-9677067-B2 Compositions and methods for synthetic gene assembly Twist Bioscience Corporation (US) 2017-06-13 US claimed
US-20170159044-A1 COMPOSITIONS AND METHODS FOR SYNTHETIC GENE ASSEMBLY Twist Bioscience Corporation 2017-06-08 US claimed
CN-103068834-B Phosphoramidites for reverse RNA synthesis 坎姆根公司 2016-10-26 CN claimed
US-5650510-A VIRICIDES OR ANTITUMOR AGENTS INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) 1997-07-22 US claimed
EP-0398231-B1 Nucleoside analogs ACAD OF SCIENCE CZECH REPUBLIC (CZ) 1997-07-16 EP claimed
EP-0630381-B1 ANTIVIRAL ACYCLIC PHOSPHONOMETHOXYALKYL SUBSTITUTED, ALKENYL AND ALKYNYL PURINE AND PYRIMIDINE DERIVATIVES ACAD OF SCIENCE CZECH REPUBLIC (CZ) 1997-04-09 EP claimed
EP-0269947-B2 Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives ACAD OF SCIENCE CZECH REPUBLIC (CS) 1996-10-16 EP claimed
US-5386030-A Chemical intermediates INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCE OF THE CZECH REPUBLIC (CZ) 1995-01-31 US claimed
EP-0630381-A4 ANTIVIRAL ACYCLIC PHOSPHONOMETHOXYALKYL SUBSTITUTED, ALKENYL AND ALKYNYL PURINE AND PYRIMIDINE DERIVATIVES. 1995-01-04 EP claimed
EP-0630381-A1 ANTIVIRAL ACYCLIC PHOSPHONOMETHOXYALKYL SUBSTITUTED, ALKENYL AND ALKYNYL PURINE AND PYRIMIDINE DERIVATIVES. ACAD OF SCIENCE CZECH REPUBLIC (CS) 1994-12-28 EP claimed
US-5208221-A Nucleotides and intermediates for herpes virus or leukemia virus BRISTOL-MYERS SQUIBB COMPANY (US) 1993-05-04 US claimed
WO-1993007157-A1 ANTIVIRAL ACYCLIC PHOSPHONOMETHOXYALKYL SUBSTITUTED, ALKENYL AND ALKYNYL PURINE AND PYRIMIDINE DERIVATIVES INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OFTHE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) 1993-04-15 WO claimed
EP-0269947-A1 Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) 1988-06-08 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250295658-A1 ANTIPARASITIC AGENTS AND METHODS DHFR, DHODH, MTHFD1 ALDH1A1 2477/4885KDM4E 3659/4885LMNA 3247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.